Lung cancer: First-in-man phase I trial with lorlatinib

被引：1
|
作者：
Romero D.
机构：
来源：
Nature Reviews Clinical Oncology | 2018年 / 15卷 / 1期
关键词：
D O I：
10.1038/nrclinonc.2017.201
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：7 / 7
相关论文
共 50 条
  • [21] Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial results
    Marc Gotkine
    Yoseph Caraco
    Yossef Lerner
    Simcha Blotnick
    Maor Wanounou
    Shalom Guy Slutsky
    Judith Chebath
    Graciela Kuperstein
    Elena Estrin
    Tamir Ben-Hur
    Arik Hasson
    Kfir Molakandov
    Tehila Sonnenfeld
    Yafit Stark
    Ariel Revel
    Michel Revel
    Michal Izrael
    Journal of Translational Medicine, 21
  • [22] Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx®) in ALS patients: phase I/IIa clinical trial results
    Gotkine, Marc
    Caraco, Yoseph
    Lerner, Yossef
    Blotnick, Simcha
    Wanounou, Maor
    Slutsky, Shalom Guy
    Chebath, Judith
    Kuperstein, Graciela
    Estrin, Elena
    Ben-Hur, Tamir
    Hasson, Arik
    Molakandov, Kfir
    Sonnenfeld, Tehila
    Stark, Yafit
    Revel, Ariel
    Revel, Michel
    Izrael, Michal
    JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)
  • [23] First-in-man, last in evidence?
    Brugaletta, Salvatore
    Sabate, Manel
    EUROINTERVENTION, 2013, 8 (09) : 999 - +
  • [24] First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study
    Vidal-Jove, Joan
    Serres, Xavier
    Vlaisavljevich, Eli
    Cannata, Jon
    Duryea, Alex
    Miller, Ryan
    Merino, Xavier
    Velat, Manuela
    Kam, Yossi
    Bolduan, Ryan
    Amaral, Joseph
    Hall, Timothy
    Xu, Zhen
    Lee, Fred T., Jr.
    Ziemlewicz, Timothy J.
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2022, 39 (01) : 1115 - 1123
  • [25] Vaccine against toxic shock syndrome in a first-in-man clinical trial
    Roetzer, Andreas
    Jilma, Bernd
    Eibl, Martha M.
    EXPERT REVIEW OF VACCINES, 2017, 16 (02) : 81 - 83
  • [26] More on first-in-man studies
    Ritter, J. M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (05) : 629 - 630
  • [27] MISAGO 1: first-in-man clinical trial with Misago™ nitinol stent
    Schulte, Karl-Ludwig
    Mueller-Huelsbeck, Stefan
    Cao, Piergiorgio
    Becquemin, Jean-Pierre
    Langhoff, Ralf
    Charalambous, Nikolas
    Desgranges, Pascal
    Kobeiter, Hicham
    Midulla, Marco
    Borovicanin, Vladimir
    Paunovic, Dragica
    Beregi, Jean-Paul
    EUROINTERVENTION, 2010, 5 (06) : 687 - 691
  • [28] Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study
    Thrower, S. L.
    James, L.
    Hall, W.
    Green, K. M.
    Arif, S.
    Allen, J. S.
    Van-Krinks, C.
    Lozanoska-Ochser, B.
    Marquesini, L.
    Brown, S.
    Wong, F. S.
    Dayan, C. M.
    Peakman, M.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 155 (02): : 156 - 165
  • [29] A first-in-man phase I study of TH-302, a hypoxia-activated cytotoxic prodrug
    Weiss, G. J.
    Infante, J. R.
    Borad, M.
    Langmuir, V. K.
    Kroll, S.
    Jung, D.
    Tibes, R.
    Chiorean, E. G.
    Jones, S. F.
    Burris, H. A.
    EJC SUPPLEMENTS, 2008, 6 (12): : 129 - 130
  • [30] First-in-man study of tafluposide, a novel inhibitor of topoisomerase I and II
    Delord, Jean-Pierre
    Bennouna, Jaafar
    Dieras, Veronique
    Campone, Mario
    Lefresne, Florence
    Aslanis, Vassili
    Douillard, Jean-Yves
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3380S - 3380S
12345